🔗 Share this article

Given that the US continues making sweeping revisions to its vaccine schedules, an unexpected name appears unexpectedly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by questioning coronavirus vaccines during the global health crisis and has zeroed in on possible fatalities after Covid vaccination in her short time at the FDA.

Scheduled Shifts to Pediatric Vaccine Schedule

Health officials had intended to unveil sweeping revisions to the childhood vaccine schedule in December, bringing the US with Denmark’s vaccine program, according to reports – a substantial departure that would put the US out of step with much of the global community with little proof for improved outcomes. The announcement has been pushed back until the next year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to speak at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this calendar year.

A New Direction at the FDA

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and vaccine centers as Høeg and Dr. Prasad consolidate power at the regulatory agency – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has often pushed for discontinuing specific pediatric immunization guidelines in the US in order to be more like Denmark's approach, a society with universal health coverage and a citizenry roughly the population of Wisconsin’s.

So far comments, she has kept her attention on immunizations – usually the domain of Prasad, chief of the FDA’s vaccine center – instead of medication approval.

Questions Over Qualifications

The appointee has no obvious background in pharmaceutical research, approval processes or administrative roles, which has been typical for past leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the agency head and CBER since spring.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in managing a sizeable institution. She lacks background in industry regulation.”

Previous directors of the center would “grasp laws and regulations and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Clearly, she lacks the sort of resume that prior appointees who headed the center have had.”

The drug center has an immense workload at the agency, she pointed out.

“The public just focuses on the innovative therapies, but the generic program approves thousands of generic medications. There’s a biosimilars program, non-prescription drug unit and more, and all of those must be supervised,” she explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a major administrative aspect to the job, which supervises more than 5,000 staff members. “It is a enormous management job, if you execute it properly,” the former official said.

Agency Reaction and Contentious Programs

Regarding concerns about Høeg’s qualifications and whether this assignment represents greater collaboration among regulatory chiefs on vaccines, a press secretary stated that the “concerns rely on incorrect premises”.

“Her resume aligns with the functions of her job,” the spokesperson explained, pointing to the time Dr. Høeg spent counseling the FDA commissioner on “drug safety and approval science, including computerized risk analysis and vaccine surveillance”.

In her interim role, Dr. Høeg takes over the agency head's controversial priority voucher program, a controversial rapid medication authorization process that reportedly worried her former heads. “By what process are these therapies being selected for this voucher program? Who makes the choices?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the FDA right now.”

In general, he stated, “the FDA appears to be shifting towards more relaxed regulations of pharmaceuticals, except for shots.”

Established History on Immunizations

Concerning vaccines, Høeg has a more established, if problematic, track record, some experts have noted. She published a study using unverified crowd-sourced reports to estimate the incidence of myocarditis after Covid vaccination. She advised the state of Florida top health official Joseph Ladapo, who allegedly have modified findings to suggest Covid vaccines are more dangerous than they are.

Part of her “wish list” for the new federal leadership included changing rules for new vaccines and ending “optional” vaccines, she said following the vote on a online show. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from receiving Covid vaccines.

“She’s an complete ideologue who starts off with her conclusions and works backwards to accommodate the evidence in a very disingenuous, untruthful fashion,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|